Engineering bioactive nanoparticles to rejuvenate vascular progenitor cells

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Nanotechnology

Background:

• Gestational diabetes mellitus (GDM) exposure in fetuses leads to endothelial progenitor cell (EPC) dysfunction, increasing risks for type-2 diabetes, hypertension, and cardiovascular disease.
• Existing therapies to restore endothelial function face challenges like systemic side effects and immune responses.

Purpose of the Study:

• To develop a novel strategy for rejuvenating GDM-exposed EPCs (GDM-ECFCs) using drug-loaded nanoparticles.
• To assess the efficacy of nanoparticle conjugation in restoring ECFC function and vascular network formation.

Main Methods:

• Drug-loaded liposomal nanoparticles were conjugated to the surface of GDM-exposed ECFCs (GDM-ECFCs).
• Cell viability, progenitor phenotypes, transgelin (TAGLN) expression, cell migration, and in vitro/in vivo vasculogenesis were evaluated.
• Nanoparticle conjugation's impact on ECFC function and therapeutic potential was assessed.

Main Results:

• Nanoparticle conjugation was successfully achieved without compromising ECFC viability or key progenitor phenotypes.
• Drug delivery normalized TAGLN expression and enhanced ECFC migration, crucial for vascular network development.
• Sustained stimulation with nanoparticles improved both in vitro and in vivo vasculogenesis of GDM-ECFCs.

Conclusions:

• Nanoparticle conjugation offers a promising strategy to rejuvenate GDM-ECFCs, enhancing their therapeutic capabilities.
• This approach has broad implications for treating cardiovascular complications and advancing tissue repair and regenerative medicine.
• Further research is warranted to explore this strategy for other chronic diseases involving dysfunctional vascular progenitor cells.